title: TGFBR2 gene expression and genetic association with schizophrenia.
abstract: TGFBR2 gene is a tumor suppressor gene located at chromosome 3p22, and the locus is reported to be linked with schizophrenia susceptibility. According to the previous studies, a reduced incidence of cancer is observed in schizophrenic patients compared with the general population and tumor suppressor genes may be associated with schizophrenia. We measured the mRNA expression of TGFBR2 gene in the peripheral leukocytes from 19 medication-free schizophrenics and 25 medication-free major depressive patients compared with age- and sex-matched control subjects using a quantitative real-time PCR method. We also followed up the TGFBR2 mRNA expression levels from 13 schizophrenics after several weeks - antipsychotic treatments. The TGFBR2 mRNA levels of medication free schizophrenics were significantly higher than those of control subjects and decreased to almost the same level as controls after antipsychotic treatment. On the other hand, the TGFBR2 mRNA levels of medication-free major depressive patients were not significantly different from controls. In genetic studies, we failed to find any association between the TGFBR2 gene and schizophrenia with 10 SNPs of TGFBR2 gene in Japanese subjects (279 subjects each) and there was no significant difference with haplotype analysis, either. Our results suggest that the TGFBR2 gene itself does not link to schizophrenia but that the TGFBR2 mRNA levels in the peripheral leukocytes may be a potential state marker for schizophrenia.
authors.affiliation: Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-8-15 Kuramoto-cho Tokushima 770-8503, Japan. snumata@clin.med.tokushima-u.ac.jp
authors.forename: Shusuke
authors.initials: S
authors.lastname: Numata
authors.forename: Shu-ichi
authors.initials: S
authors.lastname: Ueno
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Iga
authors.forename: Ken
authors.initials: K
authors.lastname: Yamauchi
authors.forename: Song
authors.initials: S
authors.lastname: Hongwei
authors.forename: Ryota
authors.initials: R
authors.lastname: Hashimoto
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Takeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kunugi
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Itakura
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Ohmori
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D044466:Asian People / Q000235:genetics; D010054:Brief Psychiatric Rating Scale; D016022:Case-Control Studies; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics; D003865:Major Depressive Disorder / Q000453:epidemiology; D005260:Female; D005838:Genotype; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D007962:Leukocytes / Q000378:metabolism*; D015810:Linkage Disequilibrium / Q000235:genetics; D008297:Male; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy / Q000235:genetics*
chemical_list: D014150:Antipsychotic Agents; D012333:RNA, Messenger; D018125:Receptors, Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II